[go: up one dir, main page]

AR078824A1 - Compuesto de cabazitaxel y sus usos - Google Patents

Compuesto de cabazitaxel y sus usos

Info

Publication number
AR078824A1
AR078824A1 ARP100103990A AR078824A1 AR 078824 A1 AR078824 A1 AR 078824A1 AR P100103990 A ARP100103990 A AR P100103990A AR 078824 A1 AR078824 A1 AR 078824A1
Authority
AR
Argentina
Prior art keywords
cabazitaxel
composite
prostate
treatment
cancer
Prior art date
Application number
Other languages
English (en)
Inventor
Sunil Gupta
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43567614&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR078824(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of AR078824A1 publication Critical patent/AR078824A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epoxy Compounds (AREA)

Abstract

Se refiere a un compuesto de formula (1) que puede estar en forma de base o en forma de hidrato o un solvato, en combinacion con prednisona o prednisolona, para su uso como medicamento en el tratamiento del cáncer de prostata, particularmente cáncer metastásico de prostata, especialmente para pacientes que no siguen un tratamiento basado en taxano.
ARP100103990 2009-10-29 2010-10-29 Compuesto de cabazitaxel y sus usos AR078824A1 (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US25616009P 2009-10-29 2009-10-29
US29390310P 2010-01-11 2010-01-11
US35583410P 2010-06-17 2010-06-17
US35588810P 2010-06-17 2010-06-17
US36992910P 2010-08-02 2010-08-02
US38393310P 2010-09-17 2010-09-17
US38996910P 2010-10-05 2010-10-05

Publications (1)

Publication Number Publication Date
AR078824A1 true AR078824A1 (es) 2011-12-07

Family

ID=43567614

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100103990 AR078824A1 (es) 2009-10-29 2010-10-29 Compuesto de cabazitaxel y sus usos

Country Status (31)

Country Link
US (8) US8927592B2 (es)
EP (1) EP2493466B1 (es)
JP (2) JP5566466B2 (es)
KR (1) KR101712231B1 (es)
CN (1) CN102770131A (es)
AR (1) AR078824A1 (es)
AU (4) AU2010310986A1 (es)
BR (1) BR112012011457A2 (es)
CA (1) CA2779009A1 (es)
CR (1) CR20120204A (es)
DK (1) DK2493466T3 (es)
EA (1) EA024186B1 (es)
EC (1) ECSP12011836A (es)
ES (1) ES2862340T3 (es)
GT (1) GT201200123A (es)
IL (3) IL219443A0 (es)
MA (1) MA33767B1 (es)
MX (1) MX336339B (es)
MY (1) MY164086A (es)
NI (1) NI201200071A (es)
PE (1) PE20121429A1 (es)
PH (1) PH12012500848A1 (es)
PL (1) PL2493466T3 (es)
PT (1) PT2493466T (es)
SG (1) SG10201810928SA (es)
SV (1) SV2012004192A (es)
TN (1) TN2012000188A1 (es)
TW (2) TWI533866B (es)
UY (1) UY32987A (es)
WO (1) WO2011051894A1 (es)
ZA (1) ZA201203123B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2926551A1 (fr) 2008-01-17 2009-07-24 Aventis Pharma Sa Formes cristallines du dimethoxy docetaxel et leurs procedes de preparation
US20120065255A1 (en) * 2009-10-19 2012-03-15 Nagesh Palepu Cabazitaxel formulations and methods of preparing thereof
EP2493466B1 (en) 2009-10-29 2021-03-10 Sanofi Mature IP Novel antitumoral use of cabazitaxel
EA023950B1 (ru) * 2011-04-12 2016-07-29 Тева Фармасьютикалз Интернэшнл Гмбх Твердофазные формы кабазитаксела и способы их получения
CN102503913B (zh) * 2011-10-20 2014-03-26 江苏红豆杉生物科技股份有限公司 直接用于x射线单晶衍射分析的二甲氧基紫杉烷类化合物单晶晶体的制备方法
JP6025861B2 (ja) * 2011-12-13 2016-11-16 アベンティス・ファーマ・ソシエテ・アノニム カバジタキセルの結晶形およびこれを調製するための方法
WO2013111157A1 (en) * 2012-01-03 2013-08-01 Shilpa Medicare Limited Process for preparing amorphous cabazitaxel
CN104583189A (zh) 2012-07-31 2015-04-29 永信药品工业股份有限公司 非晶型的卡巴利他索
TW201438714A (zh) * 2013-03-04 2014-10-16 Aventis Pharma Sa 卡巴他賽（ｃａｂａｚｉｔａｘｅｌ）及其治療轉移性前列腺癌之用途
EP2815749A1 (en) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
JP6841772B2 (ja) * 2015-02-17 2021-03-10 エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム 前立腺癌の処置におけるカバジタキセルの使用
EP3093014A1 (en) * 2015-05-13 2016-11-16 Aventis Pharma S.A. Cabazitaxel and its use for treating cancer
WO2018047074A1 (en) 2016-09-07 2018-03-15 Cadila Healthcare Limited Sterile injectable compositions comprising drug micelles
US20170281651A1 (en) * 2017-03-01 2017-10-05 Corcept Therapeutics, Inc. Concomitant administration of glucocorticoid receptor modulators and cyp3a or steroidogenesis inhibitors
US20210088505A1 (en) * 2017-04-07 2021-03-25 La Jolla Institute For Allergy And Immunology Unipotent Neutrophil Progenitor Cells, Methods of Preparation, and Uses Thereof
US20250017891A1 (en) * 2023-07-04 2025-01-16 Twi Pharmaceuticals, Inc. Pharmaceutical composition comprising cabazitaxel prodrug-cyclodextrin inclusion complex, and applications thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US5005588A (en) 1989-10-13 1991-04-09 David Rubin Method for increasing tumor sensitivity to chemotherapy
US5714512A (en) 1991-07-08 1998-02-03 Rhone-Poulenc Rorer, S.A. Compositions containing taxane derivatives
US5750561A (en) 1991-07-08 1998-05-12 Rhone-Poulenc Rorer, S.A. Compositions containing taxane derivatives
US5698582A (en) 1991-07-08 1997-12-16 Rhone-Poulenc Rorer S.A. Compositions containing taxane derivatives
FR2698543B1 (fr) 1992-12-02 1994-12-30 Rhone Poulenc Rorer Sa Nouvelles compositions à base de taxoides.
FR2698871B1 (fr) 1992-12-09 1995-02-24 Rhone Poulenc Rorer Sa Nouveau taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
FR2732340B1 (fr) 1995-03-27 1997-04-30 Rhone Poulenc Rorer Sa Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
ZA94128B (en) 1993-02-01 1994-08-19 Univ New York State Res Found Process for the preparation of taxane derivatives and betalactam intermediates therefor
US6372780B2 (en) 1995-03-27 2002-04-16 Aventis Pharma S.A. Methods of treating cell lines expressing multidrug resistance P-glycoprotein
US5847170A (en) 1995-03-27 1998-12-08 Rhone-Poulenc Rorer, S.A. Taxoids, their preparation and pharmaceutical compositions containing them
MA23823A1 (fr) 1995-03-27 1996-10-01 Aventis Pharma Sa Nouveaux taxoides, leur preparation et les compositions qui les contiennent
FR2745814B1 (fr) 1996-03-06 1998-04-03 Rhone Poulenc Rorer Sa Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2771092B1 (fr) 1997-11-18 1999-12-17 Rhone Poulenc Rorer Sa Procede de preparation de derives de la classe des taxoides
US6346543B1 (en) 1998-08-17 2002-02-12 Aventis Pharma S.A. Use of a taxoid to treat abnormal cell proliferation in the brain
KR20010079665A (ko) 1998-08-20 2001-08-22 추후제출 탁소이드 유도체의 신규 용도
US6403634B1 (en) 1999-01-13 2002-06-11 Aventis Pharma S.A. Use of taxoid derivatives
US20040126379A1 (en) 2002-08-21 2004-07-01 Boehringer Ingelheim International Gmbh Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents
DE50301051D1 (de) 2003-07-02 2005-09-29 Scheuten Glasgroep Venlo Verfahren zur Herstellung einer Brandschutzverglasung
EP1498120A1 (en) 2003-07-18 2005-01-19 Aventis Pharma S.A. Semi-solid formulations for the oral administration of taxoids
FR2859996B1 (fr) * 2003-09-19 2006-02-03 Aventis Pharma Sa Solvat acetonique du dimethoxy docetaxel et son procede de preparation
GB0425854D0 (en) 2004-11-25 2004-12-29 Astrazeneca Ab Therapeutic treatment
BRPI0518884A2 (pt) 2004-12-08 2008-12-30 Aventis Pharma Inc mÉtodo para medir a resistÊncia ou sensibilidade ao docetaxel
EP1700596A1 (en) 2005-03-09 2006-09-13 Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. Use of microtubule stabilizing compounds for the treatment of lesions of CNS axons
AR054215A1 (es) 2006-01-20 2007-06-13 Eriochem Sa Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit
FR2922107B1 (fr) 2007-10-10 2010-02-26 Aventis Pharma Sa Nouvelles compositions a base de taxoides
FR2926551A1 (fr) 2008-01-17 2009-07-24 Aventis Pharma Sa Formes cristallines du dimethoxy docetaxel et leurs procedes de preparation
EP2177630A1 (en) 2008-10-02 2010-04-21 Institut Gustave Roussy Methods for predicting or monitoring whether a patient affected by a cancer is responsive to a treatment with a molecule of the taxoid family
US9427418B2 (en) 2009-02-23 2016-08-30 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
BRPI1014854A2 (pt) 2009-03-30 2016-05-03 Cerulean Pharma Inc "conjugados polímero-agente, partículas, composições, e métodos de uso relacionados"
FR2945211A1 (fr) 2009-05-06 2010-11-12 Sanofi Aventis Combinaison antitumorale comprenant la cabazitaxel et la capecitabine
CA2939165A1 (en) 2009-09-15 2011-03-24 Cerulean Pharma Inc. A cdp-camptothecin conjugate, particle or composition and uses thereof
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
EP2493466B1 (en) 2009-10-29 2021-03-10 Sanofi Mature IP Novel antitumoral use of cabazitaxel
EP2330100B1 (en) 2009-11-04 2017-01-11 Emcure Pharmaceuticals Limited An improved process for preparation of taxane derivatives
EA201200617A1 (ru) 2009-11-23 2012-11-30 Серулин Фарма Инк. Полимеры на основе циклодекстрина для доставки лекарственных средств
WO2011124669A1 (en) 2010-04-08 2011-10-13 Institut Gustave Roussy Methods for predicting or monitoring whether a patient affected by a cancer is responsive to a treatment with a molecule of the taxoid family
WO2011130317A2 (en) 2010-04-13 2011-10-20 Amplyx Pharmaceuticals Inc. Therapeutic agents having reduced toxicity
AU2011239569B2 (en) 2010-04-16 2014-07-24 Baylor College Of Medicine Method for treating solid tumors
EP3093014A1 (en) 2015-05-13 2016-11-16 Aventis Pharma S.A. Cabazitaxel and its use for treating cancer
EP3808345A1 (en) 2019-10-15 2021-04-21 Sanofi Mature IP Cabazitaxel in mcrpc patients previously treated with docetaxel and who failed a prior androgen signaling targeted inhibitor agent

Also Published As

Publication number Publication date
AU2010310986A1 (en) 2012-06-14
US8927592B2 (en) 2015-01-06
TW201611831A (en) 2016-04-01
BR112012011457A2 (pt) 2016-05-03
JP2014196323A (ja) 2014-10-16
WO2011051894A1 (en) 2011-05-05
MA33767B1 (fr) 2012-11-01
EA201270606A1 (ru) 2013-01-30
TN2012000188A1 (en) 2013-12-12
AU2016200598A1 (en) 2016-02-25
ZA201203123B (en) 2013-06-26
US20210169843A1 (en) 2021-06-10
TWI654975B (zh) 2019-04-01
KR20120093986A (ko) 2012-08-23
US20150104411A1 (en) 2015-04-16
CR20120204A (es) 2012-07-04
IL267583A (en) 2019-08-29
JP5566466B2 (ja) 2014-08-06
US20150118182A1 (en) 2015-04-30
IL219443A0 (en) 2012-06-28
US20240139146A1 (en) 2024-05-02
US20180125810A1 (en) 2018-05-10
AU2017232227B2 (en) 2019-06-06
PH12012500848A1 (en) 2016-02-08
MY164086A (en) 2017-11-30
EA024186B1 (ru) 2016-08-31
CN102770131A (zh) 2012-11-07
PL2493466T3 (pl) 2021-11-15
CA2779009A1 (en) 2011-05-05
IL250254A0 (en) 2017-03-30
SG10201810928SA (en) 2019-01-30
US12453712B2 (en) 2025-10-28
ES2862340T3 (es) 2021-10-07
EP2493466A1 (en) 2012-09-05
US10716777B2 (en) 2020-07-21
TWI533866B (zh) 2016-05-21
JP2013509394A (ja) 2013-03-14
TW201127374A (en) 2011-08-16
MX336339B (es) 2016-01-14
DK2493466T3 (da) 2021-04-26
GT201200123A (es) 2013-11-07
AU2017232227A1 (en) 2017-10-12
EP2493466B1 (en) 2021-03-10
US20200155497A1 (en) 2020-05-21
UY32987A (es) 2011-05-31
JP6182510B2 (ja) 2017-08-16
KR101712231B1 (ko) 2017-03-03
US20190151278A1 (en) 2019-05-23
US20120301425A1 (en) 2012-11-29
NI201200071A (es) 2012-08-20
SV2012004192A (es) 2012-08-23
AU2019203514A1 (en) 2019-06-06
PT2493466T (pt) 2021-03-29
US10583110B2 (en) 2020-03-10
MX2012005030A (es) 2012-12-05
PE20121429A1 (es) 2012-11-06
ECSP12011836A (es) 2012-07-31

Similar Documents

Publication Publication Date Title
AR078824A1 (es) Compuesto de cabazitaxel y sus usos
CU20120042A7 (es) (heteroarilmetil)tiohidantoínas sustituidas como drogas anticáncer
PE20141381A1 (es) Terapia de combinacion que comprende un inhibidor de cdk4/6 y un inhibidor de pi3k para el uso en el tratamiento de cancer
CL2007002994A1 (es) Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
BR112015016681A8 (pt) uso de nanopartículas compreendendo paclitaxel e uma albumina, kit, medicamento, composição e forma de dosagem unitária para tratamento de câncer pancreático
CL2012001405A1 (es) Compuestos derivados de espiroindolinona-pirrolidinas; proceso de obtención; composicion farmaceutica; y uso en el tratamiento o profilaxis del cancer.
CL2012000772A1 (es) Compuestos derivados de hetorociclos carboxamidicos sustituidos, antagonista ar; composición farmacéutica que los comprende; y uso en el tratamiento del cáncer de próstata.
MX2010000465A (es) Metodos y composiciones para el tratamiento de cancer, tumores y alteraciones relacionadas con tumores.
PE20141792A1 (es) Formas polimorficas de (s)-2-(1-(9h-purin-6-ilamino)propil)-5-fluor-3-fenilquinazolin-4(3h)-ona
BR112015029386A2 (pt) uso de eribulina e lenvatinibe como terapia de combinação para tratamento de câncer
CL2008001047A1 (es) Compuestos derivados de difenil-dihidro-imidazopiridinonas; inhibidores de mdm2-p53;composicion farmaceutica;y uso para preparar un medicamento destinado al tratamiento o control de tumores solidos,tales como:tumores de mama.de colon,de pulmon o de prostata.
CO7180225A2 (es) Tratamientos de combinación para melanoma que comprenden la administración de cobimetinib y vemurafenib
CL2015003595A1 (es) Inhibidores/antiandrógenos novedosos de cyp17
CL2015000715A1 (es) Anti-androgenos para el tratamiento de cáncer prostatico no metastasico y resistente de castracion
CL2015001202A1 (es) Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer.
CL2013003324A1 (es) Composicion que comprende quimioterapia con paclitaxel y carboplatino y un oligonucleotido anti-clusterina; uso de la composición para el tratamiento de un paciente humano que padece cancer de pulmón.
CL2011002774A1 (es) Combinacion farmaceutica que comprende cabazitaxel y capecitabina, en forma de base, sal, hidrato o solvato; uso para el tratamiento del cancer de mama metastasico.
CL2011000168A1 (es) Compuestos derivados de narciclasina y pancratistatina; procedimiento de preparación; composición farmacéutica; combinación farmacéutica; y su uso para el tratamiento del cáncer.
EA201200190A1 (ru) Фулвестрант в дозе 500 мг для лечения распространенного рака молочной железы
CL2015002454A1 (es) Cabazitaxel y su uso para el tratamiento de los cánceres de próstata metastásicos.
CL2015001574A1 (es) Terapia combinada para el cancer
NI201100228A (es) Procedimientos de uso del factor liberador de corticotropina para el tratamiento de cáncer.
CL2008001322A1 (es) Compuestos derivados de triazolil-aminopirimidina, sustituida con heterociclos; composicion farmaceutica; y uso en el tratamiento del cancer.
MX2017014463A (es) Cabazitaxel y su uso para tratar cancer.
CO6531492A2 (es) Nuevo uso antitumoral de cabazitaxel

Legal Events

Date Code Title Description
FB Suspension of granting procedure